Modified administration schedule of adriamycin in solid tumors

Area of Science:

• Oncology
• Pharmacology

Background:

• Advanced solid tumors present significant treatment challenges.
• Adriamycin (doxorubicin) is a key chemotherapeutic agent, but its administration schedule impacts efficacy and toxicity.

Purpose of the Study:

• To evaluate the efficacy and toxicity of a modified Adriamycin administration schedule in patients with advanced solid tumors.
• To determine response rates and remission durations in specific cancer types, including breast and ovarian cancer.

Main Methods:

• Eighty-one patients with advanced solid tumors received Adriamycin at 40 mg/m2 over two days, with 3-week rest periods.
• Response rates and remission durations were assessed for various tumor types.
• Intrapleural Adriamycin was administered to patients with malignant pleural effusions.

Main Results:

• An overall response rate of 46% was observed.
• Specific response rates included 56% for breast cancer and 48% for ovarian cancer.
• Remission durations were notable in breast cancer (median 4.5 months) and ovarian cancer (median 3.2 months).
• Intrapleural Adriamycin showed a low response rate (26%) for malignant pleural effusions.
• The modified schedule exhibited decreased toxicity, with low rates of myelosuppression and oral ulceration.

Conclusions:

• The modified Adriamycin schedule demonstrates significant antitumor activity, particularly in breast and ovarian cancers, and soft tissue sarcomas.
• Squamous cell carcinoma of the esophagus also responded positively to this Adriamycin therapy.
• This administration schedule offers a potentially less toxic alternative for Adriamycin treatment.